Abstract: The present invention relates to copolymers made from a polymerization mixture comprising (a) one or more polymerizable monomers, which monomers are characterized as having at least one vinylic group and not containing an amino acid residue, (b) one or more not-functionalized side chain-linked amino acids, (c) one or more functionalized side chain-linked amino acids, (d) a free radical initiator and, optionally, (e) a chain-transfer-agent. It also relates to block copolymers comprising the same monomers. The invention also encompasses silicone hydrogel contact lenses coated with or comprising the latter copolymers and block copolymers as well methods for introducing the copolymers and block copolymers into silicone hydrogel contact lenses.

Abstract: The present invention relates to copolymers made from a polymerization mixture comprising (a) one or more polymerizable monomers, which monomers are characterized as having at least one vinylic group and not containing an amino acid residue, (b) one or more not-functionalized side chain-linked amino acids, (c) one or more functionalized side chain-linked amino acids, (d) a free radical initiator and, optionally, (e) a chain-transfer-agent. It also relates to block copolymers comprising the same monomers. The invention also encompasses silicone hydrogel contact lenses coated with or comprising the latter copolymers and block copolymers as well methods for introducing the copolymers and block copolymers into silicone hydrogel contact lenses.

Abstract: The present invention relates to safety delivery systems for intracameral administration of an appropriate dose of cefuroxime subsequent to cataract and other eye surgery. A preferred embodiment of an cefuroxime safety delivery system according to the invention comprises (a) a perforable sterile vial sterile-filled with a measured amount of cefuroxime, (b) a reconstitution syringe with a male luer fitting sterile-filled with 0.1 ml of isotonic salt solution per mg cefuroxime in the perforable vial and a vial adapter with a female luer fitting or one or more needles with female luer fitting, and (c) one or more sterilized delivery syringes with male luer fitting, each delivery syringe being capable of holding at least 0.1 ml of ejectable liquid and containing a marking indicating a fill volume of 0.1 ml of ejectable liquid.

Abstract: The invention relates to highly biocompatible or biophilic un-cross-linked or cross-linked polymers comprising one or more side-chain active acrylic amino acids of formula I wherein: X is —NH(CH2)4—, —O—C6H4—CH2—, —OCH2—, —O—CH(CH3)—, —S—CH2—, —O-proline, and R is H or CH3; and wherein the polymer further includes a free radical initiator and, optionally, a cross-linking agent having a plurality of polymerizable ethylenically unsaturated groups. The invention further concerns various highly biocompatible, cross-linked co-polymers comprising one or more monomers of formula I, and one or more other polymerizable monomers. Uses of such polymers and co-polymers for the production of contact lenses, intraocular lenses, implants, wound healing slabs, additives for food and cosmetics, conductive plastics, spinnable fibers, and the like are disclosed.

Abstract: The subject invention relates to a method of preparing a biocompatible polymer comprising epsilon-linked L-lysine having free alpha-amino and carboxy functions. The invention further encompasses the resulting biocompatible polymer and articles made from the polymer, in particular contact and intraocular lenses.

Abstract: The present invention relates to safety delivery systems for intracameral administration of an appropriate dose of cefuroxime subsequent to cataract and other eye surgery. A preferred embodiment of an cefuroxime safety delivery system according to the invention comprises (a) a perforable sterile vial sterile-filled with a measured amount of cefuroxime, (b) a reconstitution syringe with a male luer fitting sterile-filled with 0.1 ml of isotonic salt solution per mg cefuroxime in the perforable vial and a vial adapter with a female luer fitting or one or more needles with female luer fitting, and (c) one or more sterilized delivery syringes with male luer fitting, each delivery syringe being capable of holding at least 0.1 ml of ejectable liquid and containing a marking indicating a fill volume of 0.1 ml of ejectable liquid.